阿利西尤单抗联合高强度他汀对急性心肌梗死患者冠状动脉粥样硬化的影响:PACMAN-AMI随机临床试验
PACMAN-AMI双盲安慰剂对照随机临床试验纳入300例因急性心肌梗死接受经皮冠状动脉介入治疗的患者,随机接受阿利西尤单抗150 mg每两周皮下注射(n=148)或安慰剂(n=152),在急诊PCI后24小时内启动,联合瑞舒伐他汀20 mg治疗52周。主要终点为IVUS衍生的斑块体积百分比变化,阿利西尤单抗组-2.13% vs 安慰剂组-0.92%,差异-1.21%(95%CI -1.78%至-0.65%,P<.001)。近红外光谱最大脂质核心负荷指数4 mm内变化分别为-79.42 vs -37.60,差异-41.24(95%CI -70.71至-11.77,P=.006);光学相干断层扫描最小纤维帽厚度变化分别为62.67 μm vs 33.19 μm,差异29.65 μm(95%CI 11.75-47.55,P=.001)。不良事件发生率阿利西尤单抗组70.7% vs 安慰剂组72.8%。
要点
- 急性心肌梗死PCI术后24小时内启动阿利西尤单抗150 mg每两周皮下注射联合瑞舒伐他汀20 mg,52周时斑块体积百分比变化-2.13% vs 安慰剂-0.92%,差异-1.21%(95%CI -1.78%至-0.65%,P<.001)。
- 近红外光谱最大脂质核心负荷指数4 mm内变化阿利西尤单抗组-79.42 vs 安慰剂组-37.60,差异-41.24(95%CI -70.71至-11.77,P=.006)。
- 光学相干断层扫描最小纤维帽厚度变化阿利西尤单抗组62.67 μm vs 安慰剂组33.19 μm,差异29.65 μm(95%CI 11.75-47.55,P=.001)。
- 不良事件发生率阿利西尤单抗组70.7% vs 安慰剂组72.8%。
适用人群与场景
- 因急性心肌梗死接受经皮冠状动脉介入治疗的患者,在9所欧洲学术医院入组。
- 纳入300例,平均(SD)年龄58.5(9.7)岁,女性56例(18.7%),平均(SD)低密度脂蛋白胆固醇水平152.4(33.8)mg/dL。
处置流程与药物剂量
- 阿利西尤单抗150 mg每两周皮下注射(n=148),在急诊经皮冠状动脉介入治疗罪犯病变后24小时内启动,疗程52周,联合高强度他汀治疗(瑞舒伐他汀20 mg)。
- 安慰剂组(n=152)同样在急诊经皮冠状动脉介入治疗罪犯病变后24小时内启动,疗程52周,联合高强度他汀治疗(瑞舒伐他汀20 mg)。
研究设计与关键结果
- PACMAN-AMI为双盲、安慰剂对照随机临床试验,入组时间2017年5月9日至2020年10月7日,最终随访2021年10月13日,在9所欧洲学术医院纳入300例因急性心肌梗死接受经皮冠状动脉介入治疗的患者。
- 随机分为阿利西尤单抗组(150 mg每两周皮下注射,n=148)或安慰剂组(n=152),均在急诊经皮冠状动脉介入治疗罪犯病变后24小时内启动,疗程52周,联合瑞舒伐他汀20 mg治疗。
- 在基线及52周时对2条非梗死相关冠状动脉行血管内超声、近红外光谱和光学相干断层扫描系列检查;265例(88.3%)完成537条动脉的系列血管内超声成像。
- 主要疗效终点为基线至52周血管内超声衍生的斑块体积百分比变化:阿利西尤单抗组-2.13% vs 安慰剂组-0.92%,差异-1.21%(95%CI -1.78%至-0.65%,P<.001)。
- 次要终点近红外光谱衍生的4 mm内最大脂质核心负荷指数变化:阿利西尤单抗组-79.42 vs 安慰剂组-37.60,差异-41.24(95%CI -70.71至-11.77,P=.006)。
- 次要终点光学相干断层扫描衍生的最小纤维帽厚度变化:阿利西尤单抗组62.67 μm vs 安慰剂组33.19 μm,差异29.65 μm(95%CI 11.75-47.55,P=.001)。
- 不良事件发生率阿利西尤单抗组70.7% vs 安慰剂组72.8%。
证据类型、等级与局限
- 证据类型:双盲、安慰剂对照随机临床试验。
- 局限:作者指出需要进一步研究以了解阿利西尤单抗是否改善该人群的临床结局。
对床旁实践的改变
- 对于因急性心肌梗死接受经皮冠状动脉介入治疗的患者,作者认为在急诊PCI后24小时内启动阿利西尤单抗150 mg每两周皮下注射联合瑞舒伐他汀20 mg治疗52周,可显著促进非梗死相关动脉的冠状动脉斑块消退。
- 作者指出需要进一步研究以了解阿利西尤单抗是否改善该人群的临床结局。
指南或共识出处
- PACMAN-AMI随机临床试验(ClinicalTrials.gov Identifier: NCT03067844)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Coronary plaques that are prone to rupture and cause adverse cardiac events are characterized by large plaque burden, large lipid content, and thin fibrous caps. Statins can halt the progression of coronary atherosclerosis; however, the effect of the proprotein convertase subtilisin kexin type 9 inhibitor alirocumab added to statin therapy on plaque burden and composition remains largely unknown.
OBJECTIVE: To determine the effects of alirocumab on coronary atherosclerosis using serial multimodality intracoronary imaging in patients with acute myocardial infarction.
DESIGN, SETTING, AND PARTICIPANTS: The PACMAN-AMI double-blind, placebo-controlled, randomized clinical trial (enrollment: May 9, 2017, through October 7, 2020; final follow-up: October 13, 2021) enrolled 300 patients undergoing percutaneous coronary intervention for acute myocardial infarction at 9 academic European hospitals.
INTERVENTIONS: Patients were randomized to receive biweekly subcutaneous alirocumab (150 mg; n = 148) or placebo (n = 152), initiated less than 24 hours after urgent percutaneous coronary intervention of the culprit lesion, for 52 weeks in addition to high-intensity statin therapy (rosuvastatin, 20 mg).
MAIN OUTCOMES AND MEASURES: Intravascular ultrasonography (IVUS), near-infrared spectroscopy, and optical coherence tomography were serially performed in the 2 non-infarct-related coronary arteries at baseline and after 52 weeks. The primary efficacy end point was the change in IVUS-derived percent atheroma volume from baseline to week 52. Two powered secondary end points were changes in near-infrared spectroscopy-derived maximum lipid core burden index within 4 mm (higher values indicating greater lipid content) and optical coherence tomography-derived minimal fibrous cap thickness (smaller values indicating thin-capped, vulnerable plaques) from baseline to week 52.
RESULTS: Among 300 randomized patients (mean [SD] age, 58.5 [9.7] years; 56 [18.7%] women; mean [SD] low-density lipoprotein cholesterol level, 152.4 [33.8] mg/dL), 265 (88.3%) underwent serial IVUS imaging in 537 arteries. At 52 weeks, mean change in percent atheroma volume was -2.13% with alirocumab vs -0.92% with placebo (difference, -1.21% [95% CI, -1.78% to -0.65%], P < .001). Mean change in maximum lipid core burden index within 4 mm was -79.42 with alirocumab vs -37.60 with placebo (difference, -41.24 [95% CI, -70.71 to -11.77]; P = .006). Mean change in minimal fibrous cap thickness was 62.67 μm with alirocumab vs 33.19 μm with placebo (difference, 29.65 μm [95% CI, 11.75-47.55]; P = .001). Adverse events occurred in 70.7% of patients treated with alirocumab vs 72.8% of patients receiving placebo.
CONCLUSIONS AND RELEVANCE: Among patients with acute myocardial infarction, the addition of subcutaneous biweekly alirocumab, compared with placebo, to high-intensity statin therapy resulted in significantly greater coronary plaque regression in non-infarct-related arteries after 52 weeks. Further research is needed to understand whether alirocumab improves clinical outcomes in this population.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03067844.
参考来源
- Räber L, Ueki Y, Otsuka T, et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA. 2022. PMID: 35368058. doi:10.1001/jama.2022.5218
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。